Study Suggests COVID-19 Antiviral Nirmatrelvir Only Benefits Older Adults
Researchers identified a total of 109,254 eligible CHS members with COVID-19 who were 40 years of age and older and at high risk for progression to severe disease.
Diagnosis & Disease Information
Study Shows Bivalent RSV Vaccine Candidate Provides Protection for Older Adults
The RSVpreF vaccine candidate consists of 2 prefusion F proteins selected to optimize protection against RSV A and B.
Xofluza Approved to Treat, Prevent Influenza in Pediatric Patients
The expanded approval was based on data from two phase 3 studies, miniSTONE-2 and BLOCKSTONE.
FDA Authorizes Intradermal Use of Jynneos to Increase Supply During Monkeypox Outbreak
Under the EUA, Jynneos can be administered either intradermally for individuals aged ≥18 years or subcutaneously for individuals aged <18 years.
Vaccines for Monkeypox Prevention: Jynneos and ACAM2000
An individual is considered fully vaccinated about 2 weeks after the second dose of Jynneos and 4 weeks after receiving ACAM2000.
Lesion Swab Samples Should Be Used to Test for Monkeypox
The Agency warned that use of an alternate sample type (eg, blood, saliva) may lead to false test results.
FDA: Pharmacists Allowed to Prescribe Paxlovid for COVID-19 Treatment
Paxlovid is authorized for the treatment of mild to moderate COVID-19 in certain patients who are at high risk for progression to severe disease.
HHS Expands Access to Jynneos Vaccine in Light of Monkeypox Outbreak
In total, 1.6 million doses of the Jynneos vaccine will be available this year.
Pfizer-BioNTech Omicron-Adapted COVID-19 Vaccine Candidates Elicit Strong Immune Response
The trial evaluated booster doses of the Omicron-adapted vaccine candidates.
Flucelvax Quadrivalent Approval Expanded to Include Younger Patients
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine.
- Loading...
Loading...
Next post in Pediatrics
Loading... 
Loading...